Pharmacologic management of spasticity in cerebral palsy

Journal of Pediatric Orthopaedics

Volumn 23, Issue 5, 2003, Pages 679-686

  Mooney III, James F ^a   Koman, L Andrew ^b   Smith, Beth P ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALCOHOL; BACLOFEN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; DANTROLENE; DIAZEPAM; PHENOL; SNARE PROTEIN; SUBSTANCE P; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN; TIZANIDINE;

CARDIOVASCULAR DISEASE; CEREBRAL PALSY; CLINICAL TRIAL; COORDINATION; DROWSINESS; DRUG DEPENDENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; LIVER TOXICITY; MEMORY DISORDER; MUSCLE DISEASE; MUSCLE MASS; MUSCLE WEAKNESS; NAUSEA; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SPASTICITY;

EID: 0041919795     PISSN: 02716798     EISSN: None     Source Type: Journal    
DOI: 10.1097/01241398-200309000-00021     Document Type: Review

References (99)

1. Aicardi J. Diseases of the nervous system in childhood. In: Clinics in Developmental Medicine No. 115/118. London: MacKeith Press, 1992.
2. Albright AL, Barron WB, Fasick MP, et al. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA. 1993; 270:2475-2477.
3. Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA. 1991;265:1418-1422.
4. Albright AL. Spastic cerebral palsy: approaches to drug treatment. CNS Drugs. 1995;4:17-27.
5. Albright AL. Intrathecal baclofen in cerebral palsy movement disorders. J Child Neurol. 1996;11:S29-S35.
6. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001;248(Suppl 1):3-10.
7. Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol. 2002;44:666-675.
8. Barwood S, Baillieu C, Boyd R, et al. Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol. 2000;42:116-121.
9. Blickstein I. Cerebral palsy in multifoetal pregnancies. Dev Med Child Neurol. 2002;44:352-355.
10. Borodic G, Johnson E, Goodnough M, et al. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology. 1996;46:26-29.
11. Boyd R, Graham HK. Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol. 1997;4:S15-S22.
12. Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol. 1999;6:S23-S35.
13. Boyd RN, Pliatsios V, Starr R, et al. Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol. 2000;42:32-41.
14. Boyd RN, Dobson F, Parrott J, et al. The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial. Eur J Neurol. 2001;5:109-119.
15. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve. 1997;S6:S146-S168.
16. Butler C, Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACPDM Treatment Outcomes Committee Review Panel. Dev Med Child Neurol. 2000; 42:634-645.
17. Calderon-Gonzalez R, Calderon-Sepulveda RF. Pathophysiology of spasticity and the role of botulinum in its treatment. Acta Neuropediatr. 1994;1:45-57.
18. Calderon-Gonzalez R, Calderon-Sepulveda R, Rincon-Reyes M, et al. Botulinum toxin A in management of cerebral palsy. Pediatr Neurol. 1994;10:284-288.
19. Campbell SK, Almeida GL, Penn RD, et al. The effects of intrathecally administered baclofen on function in patients with spasticity. Phys Ther. 1995;75:352-362.
20. Campbell WM, Ferrel A, McLauhlin JF, et al. Long-term safety and efficacy of continuous intrathecal baclofen. Dev Med Child Neurol. 2002;44:660-665.
21. Carpenter EB. Role of nerve blocks in the foot and ankle in cerebral palsy: therapeutic and diagnostic. Foot Ankle. 1983;4:164-166.
22. Carpenter EB, Seitz DG. Intramuscular alcohol as an aid in management of spastic cerebral palsy. Dev Med Child Neurol. 1980; 22:497-501.
23. Childers MK. Rationale for localized injection of botulinum toxin type A in spasticity. Eur J Neurol. 1997;4:S37-S40.
24. Childers MK, Stacy M, Cooke DL, et al. Comparison of two injection techniques using botulinum toxin in spastic hemiplegia. Am J Phys Med Rehabil. 1996;75:462-469.
25. Corry IS, Cosgrove AP, Duffy CM. Botulinum toxin A as an alternative to serial casting in the conservative management of equinus in cerebral palsy. Dev Med Child Neurol. 1995;37:20-21.
26. Corry IS, Cosgrove AP, Walsh EG, et al. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol. 1997;39:185-193.
27. Corry IS, Cosgrove AP, Duffy CM, et al. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orrhop. 1998;18:304-311.
28. Corry IS, Cosgrove AP, Duffy CM, et al. Botulinum toxin A in hamstring spasticity. Gait Posture. 1999;10:206-210.
29. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol. 1994;36:386-396.
30. Dahlin M, Knutsson E, Nergardh A. Treatment of spasticity in children with low dose benzodiazepine. J Neurol Sci. 1993;117: 54-60.
31. de Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA. 1999;96:3200-3205.
32. Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol. 1985;17:107-116.
33. Desloovere K, Molenaers G, Jonkers I, et al. A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol. 2001;5:75-87.
34. Detrembleur C, Lejeune TM, Renders A, et al. Botulinum toxin and short-term electrical stimulation in the treatment of equinus in cerebral palsy. Mov Disord. 2002;17:162-169.
35. Dolly JO, Black J, Williams RS, et al. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature. 1984;307:457-460.
36. Eames NW, Baker R, Hill N, et al. The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response. Dev Med Child Neurol. 1999;41:226-232.
37. Fehlings D, Rang M, Glazier J, et al. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr. 2000;137:331-337.
38. Fehlings D, Rang M, Glazier J, et al. Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome. Eur J Neurol. 2001;8:145-149.
39. Flett PJ, Stern LM, Waddy H, et al. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health. 1999;35:71-77.
40. Foran P, Lawrence GW, Shone CC, et al. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry (Mosc), 1996;35:2630-2636.
41. Ford F, Bleck EE, Aptekar RG, et al. Efficacy of dantrolene sodium in the treatment of spastic cerebral palsy. Dev Med Child Neurol. 1976;18:770-783.
42. Friedman A, Diamond M, Johnston MV, et al. Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy. Am J Phys Med Rehab. 2000;79:53-59.
43. Gerszten PC, Albright AL, Johnstone GF. Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy. J Neurosurg. 1998;88:1009-1013.
44. Gilmartin R, Bruce D, Storrs BB, et al. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol. 2000;15:71-77.
45. Ginsburg GM. Progression of scoliosis in spastic quadriplegic patients after the insertion of an intrathecal baclofen pump. Dev Med Child Neurology Suppl. 2002;91:1344.
46. Hesse S, Jahnke MT, Luecke D, et al. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett. 1995;201:37-40.
47. Hesse S, Brandl-Hesse B, Seidel U, et al. Lower limb muscle activity in ambulatory children with cerebral palsy before and after the treatment with Botulinum toxin A. Restor Neurol Neurosci. 2000;17:1-8.
48. Houltram J, Noble I, Boyd RN, et al. Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation. Eur J Neurol. 2001;5:194-202.
49. Humeau Y, Doussau F, Grant NJ, et al. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie. 2000;82: 427-446.
50. Jongerius PH, Rotteveel JJ, van den Hoogen F, et al. Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series. Eur J Pediatr. 2001; 160:509-512.
51. Khalili AA, Harmel MH, Forster S, et al. Management of spasticity by selective peripheral nerve block with dilute phenol solutions in clinical rehabilitation. Arch Phys Med Rehab. 1964;45:513-519.
52. Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type A neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics. 2001;108:1062-1071.
53. Koman LA, Mooney JF, Mulvaney T, et al. Further evaluation of botulinum A toxin (BOTOX) in the management of cerebral palsy. Dev Med Child Neurol. 1993;35:29-30.
54. Koman LA, Mooney JF III, Smith B, et al. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop. 1993;13:489-495.
55. Koman LA, Mooney JF III, Smith BP, et al. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop. 1994; 14:299-303.
56. Koman LA, Mooney JF III, Smith BP, et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop. 2000;20:108-115.
57. Koman LA, Smith BP, Tingey CT, et al. The effect of botulinum toxin type A injections on the natural history of equinus foot deformity in paediatric cerebral palsy patients. Eur J Neurol. 1999;6:S19-S22.
58. Koman LA, Smith BP, Goodman A. Botulinum Toxin Type A in the Management of Cerebral Palsy. Winston-Salem: Wake Forest University Press, 2002.
59. Korenkov AI, Niendorf WR, Darwish N, et al. Continuous intrathecal infusion of baclofen in patients with spasticity caused by spinal cord injuries. Neurosurgery. 2002;25:228-230.
60. Lance JW, Burke D, Gillies JD. An electromyographic analysis of spasticity. Trans Am Neurol Assoc. 1970;95:272-274.
61. Linder M, Schindler G, Michaelis U, et al. Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure. Eur J Neurol. 2001;8:120-126.
62. Love SC, Valentine JP, Blair EM, et al. The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia: A randomized controlled trial. Eur J Neurol. 2001;5: 50-58.
63. Lu L, Atchabahian A, Mackininon SE, et al. Nerve injection injury with botulinum toxin. Plast Reconstr Surg. 1998;101:1875-1880.
64. Mason C, Gilpin P, McGowan S, et al. The effect of intrathecal baclofen on functional intelligibility of speech. Int J Lang Commun Disord. 1998;33:24-25.
65. Milanov I, Georgiev D. Mechanisms of tizanidine action on spasticity. Acta Neurol Scand. 1994;89:274-279.
66. Molenaers G, Desloovere K, Eyssen M, et al. Botulinum toxin type A treatment of cerebral palsy: An integrated approach. Eur J Neurol. 1999;6:S51-S57.
67. Molenaers G, Eyssen M, Desloovere K, et al. A multilevel approach to botulinum toxin type A treatment of the (ilio)psoas in spasticity in cerebral palsy. Eur J Neurol. 1999;6:S59-S62.
68. Moore TJ, Anderson RB. The use of open phenol blocks to the motor branches of the tibial nerve in adult acquired spasticity. Foot Ankle. 1991;11:219-221.
69. Muller H. Treatment of severe spasticity: results of a multicenter trial conducted in Germany involving the intrathecal infusion of baclofen by an implantable drug delivery system. Dev Med Child Neurol. 1992;34:739-745.
70. Murphy NA, Irwin MC, Hoff C. Intrathecal baclofen therapy in children with cerebral palsy: efficacy and complications. Arch Phys Med Rehabil. 2002;83:1721-1725.
71. O'Shea TM, Klinepeter KL. Prenatal events and the risk of cerebral palsy in very low birth weight infants. Am J Epidemiol. 1998;147:362-369.
72. O'Shea TM, Preisser JS, Klinepeter KL, et al. Trends in mortality and cerebral palsy in a geographically based cohort of very low birth weight neonates born between 1982 to 1994. Pediatrics. 1998;101(4 Pt 1):642-647.
73. Palisano R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39:214-223.
74. Pedersen E, Arlien-Soborg P, Mai J. The mode of action of the gaba derivative baclofen in human spasticity. Acta Neurol Scand. 1974;50:665-680.
75. Penn RD, Kroin JS. Intrathecal baclofen alleviates spinal cord spasticity. Lancet. 1984;1:1078.
76. Penn RD, Kroin JS. Continuous intrathecal baclofen for severe spasticity. Lancet. 1985;20:125-127.
77. Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989;320:1517-1521.
78. Sampson FC, Hayward A, Evans G, et al. Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity. J Neurosurg. 2002;96:1052-1057.
79. Scales SJ, Chen YA, Yoo BY, et al. SNAREs contribute to the specificity of membrane fusion. Neuron. 2000;26:457-464.
80. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992;359:832-835.
81. Schiavo G, Santucci A, Dasgupta BR, et al. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 1993;29;335:99-103.
82. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus. 1980;17:21-25.
83. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1983;12:924-927.
84. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disorders. 1988;3:333-335.
85. Spira R. Management of spasticity in cerebral palsied children by peripheral nerve block with phenol. Dev Med Child Neurol. 1971; 13:164-173.
86. Sutherland DH, Kaufman KR, Wyatt MP, et al. Effects of botulinum toxin on gait of patients with cerebral palsy: Preliminary results. Dev Med Child Neurol. 1994;36:11-12.
87. Sutherland DH, Kaufman KR, Wyatt MP, et al. Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: A 3-dimensional motion analysis study. Dev Med Child Neurol. 1995;37:17-18.
88. Sutherland DH, Kaufman KR, Wyatt MP, et al. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture. 1999;10:1-9.
89. Tardieu G, Tardieu C, Hariga J. Infiltrations par l'alcool a 45 degrees des points moteurs, des racines par voie epidurale, ou du nerf tibial posterieur. Leurs indications et contra-indications dans les divers modes de "spasticite" (experience de dix ans). Rev Neurol (Paris). 1971;125:63-68.
90. Tardieu G, Tardieu C, Hariga J. Selective partial denervation by alcohol injections and their results in spasticity. Reconstr Surg Traumatol. 1972;13:18-36.
91. Thompson NS, Baker RJ, Cosgrove AP, et al. Musculoskeletal modelling in determining the effect of botulinum toxin on the hamstrings of patients with crouch gait. Dev Med Child Neurol. 1998;40:622-625.
92. Ubhi T, Bhakta BB, Ives HL, et al. Randomized double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child. 2000;83:481-487.
93. Van Heest AE. Applications of botulinum toxin in orthopedics and upper extremity surgery. Techniques in Hand and Upper Extremity Surgery. 1997;1:27-34.
94. Wagstaff A, Bryson HM. Tizanidine: A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997; 53:435-452.
95. Wall SA, Chait LA, Temlett JA, et al. Botulinum A chemodenervation: a new modality in cerebral palsied hands. Br J Plast Surg. 1993;46:703-706.
96. Ward AB. Botulinum toxin type A treatment of hip and thigh spasticity: a technique for injection of psoas major muscle. Eur J Neurol. 1999;6:591-593.
97. Willenborg MJ, Shilt JS, Smith BP, et al. Technique for iliopsoas ultrasound-guided active electromyography-directed botulinum A toxin injection in cerebral palsy. J Pediatr Orthop. 2002;22:165-168.
98. Wood KM. The use of phenol as a neurolytic agent: A review. Pain. 1978;5:205-229.
99. Yadav SL, Singh U, Dureja GP, et al. Phenol block in the management of spastic cerebral palsy. Indian J Pediatr. 1994;61:249-255.